COMBINATION DRUG TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这个项目是我们对肌萎缩侧索硬化症(ALS)安全有效的神经保护疗法研究的一部分，ALS是一种进行性和不可治愈的神经退行性疾病。多种机制参与神经退行性变导致ALS神经元死亡。这项提议有几个独特的特点。首先，它将在人类肌萎缩侧索硬化症中比较影响不同神经退化机制的两种药物组合的神经保护潜力。在ALS的SOD小鼠模型中，米诺环素/肌酸和塞来昔布/肌酸的组合显示出相加的作用，比单独使用单独使用的药物更能减少神经退变和延长生存时间。其次，它将使用一项重要的新的第二阶段选择试验设计来确定哪种组合更好。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is part of our research into safe and effective neuroprotective therapies for amyotrophic lateral sclerosis (ALS), a progressive and incurable neurodegenerative disorder. Multiple mechanisms involved in neurodegeneration lead to neuronal demise in ALS. This proposal has several unique features. First, it will compare in human ALS the neuroprotective potential of two combinations of agents that influence different mechanisms of neurodegeneration. The combinations of minocycline/creatine and celecoxib/creatine have shown additive effects in the SOD mouse model of ALS, reducing neurodegeneration and prolonging survival more than individual agents alone. Second, it will use an important new phase II selection trial design to determine which combination is superior.